2022年5月30日

核酸基因治療市場的主要參與者有Celsion Corporation、Wave Life Sciences、Imugene、Caperna、Phylogica、主角治療、Benitec Biopharma、EGEN、BioMedica、Transgene和Copernicus Therapeutics。法國裏昂，2022年5月30日(環球新聞社)——Reportlinker.com宣布發布報告《2022年基於核酸的基因治療全球市場報告》——https://www.reportlinker.com/p06280834/?utm_source=GNW全球基於核酸的基因治療市場預計將從2021年的6.2億美元增長到2022年的6.8億美元，複合年增長率(CAGR)為9.5%。預計到2026年，該市場將以9.0%的複合年增長率(CAGR)增長到9.6億美元。核酸基因治療市場包括核酸基因治療產品和服務的銷售。基因療法用於糾正導致疾病發展的缺陷基因。此外，以核酸為基礎的療法被用於治療遺傳性疾病和無法永久治愈的疾病，如貧血、鐮狀細胞病、囊性纖維化、糖尿病和地中海貧血。基於核酸的基因治療技術主要有反義和抗基因、短抑製序列、基因轉移治療、核苷類似物、核酶、適體等。核苷類似物是一類重要的抗病毒藥物，通常用於治療人類免疫缺陷病毒(HIV)感染，乙型肝炎病毒(HBV)，丙型肝炎病毒(HCV)，巨細胞病毒(CMV)。各種應用包括腫瘤學、肌肉萎縮症/肌肉疾病和罕見疾病，這些應用由醫院和診所以及學術和研究機構等最終用戶使用。政府和相關公司不斷增加的資金支持預計將推動基於核酸的基因治療的需求。核酸療法是負責基因表達的天然酸或蛋白質的類似物。傳統療法無法治愈囊性纖維化、血友病、鐮狀細胞性貧血、地中海貧血和糖尿病等疾病。遺傳分析和分子目標鑒定構成了這類藥物的主幹。 Nucleic acid medication has greater potential for the treatment of these diseases, as they target the genetic basis of diseases and have a permanent cure.Rising financial support by the government and the companies dealing in the market for gene therapy is expected to contribute to increasing the demand for nucleic acid-based gene therapies. For instance, in October 2019, the USA National Institutes of Health (NIH) announced plans to invest $100 million for the next four years to cure HIV and sickle cell disease with gene therapies. The government support for gene therapies will contribute to the growth of the market. Stringent regulations imposed on gene therapies raise the price of gene therapies, which in turn hinders the demand for nucleic acid-based gene therapies.The excessive regulatory oversights create an expensive and elongated route for approval increasing the expenses. According to Foundation for Economic Education (FEE), unlike other drugs approved or regulated by the Food and Drug Administration (FDA), gene therapies are not only subject to the regulatory structure of the FDA, but also the Recombinant DNA Advisory Committee and Office of Biotechnology Activities. Also, as estimated by FEE, an approved gene therapy drug costs nearly $5.0 billion, which is five times higher than that of the average cost of FDA approval. The high cost of gene therapeutics drugs places them beyond the financial reach of the populace. This scenario is anticipated to restrain the market growth of the nucleic acid-based gene therapy market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nucleic acid-based gene therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.